 |
85 Diseases |  |
26 Trials |
|
26 Trials |  |
4615 News |  |
| «12...46474849505152535455565758» |
- | Soliris (eculizumab) / Alexion Pharma
Journal: Quantification of the IgG2/4 kappa Monoclonal Therapeutic Eculizumab from Serum Using Isotype Specific Affinity Purification and Microflow LC-ESI-Q-TOF Mass Spectrometry. (Pubmed Central) - Jun 26, 2019
We show here the ability to quantitate eculizumab with a LOQ of 5 mcg/mL by removing the higher abundance IgG1, IgG2, and IgG3 from the polyclonal background, making this approach a simple and efficient procedure. Graphical Abstract ᅟ.
- | Soliris (eculizumab) / Alexion Pharma
Biomarker, Journal: Neurology (Pubmed Central) - Jun 26, 2019
The use of levodopa-carbidopa intestinal gel and a subcutaneous apomorphine infusion allow a reduction of motor fluctuations in Parkinson's disease. Eculizumab appears as an alternative treatment in severe forms of myasthenia gravis.
- || Soliris (eculizumab) / Alexion Pharma
Post Tx DSA:13,000 class II; We treating as aHUS and ? AMR with PP, Eculizumab.. How to go ahead @arvindcanchi @drballalmanipal @BasuNephro @edgarvlermamd @divyaa24 @jradnephro (Twitter) - Jun 24, 2019
- | Soliris (eculizumab) / Alexion Pharma
Journal: Hemolytic uremic syndrome with dual caution in an infant: cobalamin C defect and complement dysregulation successfully treated with eculizumab. (Pubmed Central) - Jun 24, 2019
Eculizumab appears as an alternative treatment in severe forms of myasthenia gravis. To the best of our knowledge, our patient is the first to have Cbl C defect-HUS accompanied by complement dysregulation, who responded well to eculizumab therapy.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis. (Pubmed Central) - Jun 24, 2019
In a murine EVH model, complement-susceptible erythrocytes were completely eliminated within 3 d in control mAb-treated hP-Tg/P mice, whereas such cells were protected and persisted in hP-Tg/P mice treated with an anti-hP mAb. Collectively, these data suggest that anti-P mAbs can inhibit both IVH and EVH mediated by complement and may offer improved efficacy over eculizumab, the current standard therapy for PNH.
- | Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab. (Pubmed Central) - Jun 20, 2019
Herein we describe an 11-year-old boy with atypical hemolytic uremic syndrome treated with eculizumab who developed fatal meningococcemia due to Neisseria meningitidis serogroup Y 16 months after receiving two doses of meningococcal conjugate vaccine (MenACWY-D) while on oral penicillin prophylaxis. Clinicians need to maintain a high index of suspicion for invasive meningococcal disease in patients taking eculizumab treatment, regardless of meningococcal vaccination or antimicrobial prophylaxis status.
- | Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Atypical hemolytic-uremic syndrome as one of the causes of acute kidney injury in pregnant women. (Pubmed Central) - Jun 19, 2019
In most patients, the obstetric aHUS occurs with the development of MOF. Timely diagnosis of aHUS and immediate treatment by eculizumab allows not only to save the life of patients, but also completely restore their health.
- ||| Soliris (eculizumab) / Alexion Pharma
Clinical: 3) And finally trial of safe eculizumab discontinuation by @NationalaHUS @neil_sheerin https://t.co/mkOnMr5XCb hopefully give us more clues about how to manage our #aHUS patients safely and rationally (Twitter) - Jun 18, 2019
- ||| Soliris (eculizumab) / Alexion Pharma
Clinical: 2)However, new information are emerging, suggesting there is a possibility to withdraw eculizumab safely in specific cases. A nice example is data from the Dutch 🇱🇺 study and experience by @KioaWijnsma @Nicolevandekar (Twitter) - Jun 18, 2019
- | Soliris (eculizumab) / Alexion Pharma
Journal: Medusa's Head: The Complement System in Traumatic Brain and Spinal Cord Injury. (Pubmed Central) - Jun 17, 2019
The role of upstream classical, alternative or extrinsic complement activation cascades remains unclear. Although several issues remain to be investigated, current evidence support the investigation of a number of complement-targeting agents targeting C3 or C5, such as eculizumab, for repurposing in TBI and SCI treatment.
- | Soliris (eculizumab) / Alexion Pharma
Journal: An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. (Pubmed Central) - Jun 16, 2019
However, recently, the terminal complement inhibitor eculizumab became commercially available and has shown promising results in different open-label studies and case series. In our centre, first-line therapy is PE; however, patients are instantly switched to complement inhibitory therapy in case of treatment failure or intolerance.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Disseminated cryptococcosis associated with administration of eculizumab. (Pubmed Central) - Jun 15, 2019
In our centre, first-line therapy is PE; however, patients are instantly switched to complement inhibitory therapy in case of treatment failure or intolerance. A 23-year-old man developed fatal disseminated cryptococcosis after treatment with eculizumab.
- ||| Soliris (eculizumab) / Alexion Pharma
Clinical: Hello Juan Carlos I voted for ECU. Could you inform about the evolution of this very interesting case? thank you #eculizumabteam (Twitter) - Jun 10, 2019
- | Soliris (eculizumab) / Alexion Pharma, Avastin (bevacizumab) / Roche
Journal: Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab. (Pubmed Central) - Jun 9, 2019
Eculizumab is a terminal complement inhibitor used in the treatment of atypical hemolytic uremic syndrome. Herein, we present three cases of bevacizumab-induced atypical hemolytic syndrome treated successfully with eculizumab.
- ||| Soliris (eculizumab) / Alexion Pharma
Here some data on pregnancys with eculizumab (PNH) https://t.co/87OgZbmFuw And https://t.co/xJKlefmUkd 20 newborns with cord blood levels of eculizumab: ecu found in 7 out of 20. Levels all below 21ug/ml (Twitter) - Jun 7, 2019
- || Soliris (eculizumab) / Alexion Pharma
Limited by only reading the abstract but spoke about it @ukkw2019. Agree disappointing. No single wonder drug to treat hla ab. Outcomes no better than reported with eculizumab. Not sure cause of late graft losses/why lack of rebound dsa. Still a cool drug/PLEX substitute. (Twitter) - Jun 6, 2019
- ||| Soliris (eculizumab) / Alexion Pharma
My colleagues @NationalaHUS in Newcastle pretty adamant #PLEX adds nothing.... I have to say that if #aHUS this early unless she responds to #eculizumab pretty promptly then she is going to lose the baby. #pregnancy #kidneydisease (Twitter) - Jun 6, 2019
- ||| Soliris (eculizumab) / Alexion Pharma
Roger - Why PLEX with normal ADAMTS-13 activity? Probably needs eculizumab but not sure about teratogenicity in first trimester...Tough situation. (Twitter) - Jun 5, 2019
- ||| Soliris (eculizumab) / Alexion Pharma
With the arrival of eculizumab, there’s no clear value of PLEX in aHUS-like scenarios. In fact, this pt got 2 PLEX at an OUH before transfer and it was then stopped after ADAMTS13 returned, so I’m with Anitha here. (Twitter) - Jun 5, 2019
- | Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Fulminant meningococcal sepsis due to non-groupable Neisseria meningitidis in a patient receiving eculizumab. (Pubmed Central) - Jun 5, 2019
Herein, we present three cases of bevacizumab-induced atypical hemolytic syndrome treated successfully with eculizumab. No abstract available
- | Soliris (eculizumab) / Alexion Pharma
Journal: Deleterious Impact of a Novel CFH Splice Site Variant in Atypical Hemolytic Uremic Syndrome. (Pubmed Central) - Jun 4, 2019
Treatment with steroids, plasmapheresis, and the complement inhibitor eculizumab led to complete hematological and clinical remission after several months and stable renal function up to 6 years later. In conclusion, genetic investigation for pathogenic variants and evaluation of their functional impact, in particular in the case of splice site variants, is clinically relevant and enables not only better molecular understanding but helps to guide therapy with complement inhibitors.
- | Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Eculizumab in STEC-HUS: need for a proper randomized controlled trial. (Pubmed Central) - Jun 4, 2019
In a subgroup of patients, however, rapid neurological improvement was described. In the post-hoc-defined group of patients with favorable outcome, there was a trend towards more sustained complement inhibition, although this finding was not significant compared to patients with an unfavorable outcome.Because multiple interventions were used and the study did not include any control group, future controlled studies are urgently needed to resolve the debate as to whether eculizumab can be an effective treatment for both prevention and treatment of complications in STEC-HUS.
- | Soliris (eculizumab) / Alexion Pharma
Review, Journal: Atypical hemolytic-uremic syndrome: An update on pathophysiology, diagnosis and treatment. (Pubmed Central) - Jun 4, 2019
We discuss the pathophysiology, clinical manifestations, diagnosis, complications and management of aHUS. We also review the efficacy and safety of the novel therapeutic agent, eculizumab, in aHUS, pregnancy-associated aHUS and aHUS in renal transplant patients.
- | Soliris (eculizumab) / Alexion Pharma
Clinical, P4 data, Journal: Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. (Pubmed Central) - May 30, 2019
We also review the efficacy and safety of the novel therapeutic agent, eculizumab, in aHUS, pregnancy-associated aHUS and aHUS in renal transplant patients. This interim analysis confirmed the acceptable safety profile and effectiveness of eculizumab for Japanese adult aHUS patients in real-world settings.
- | Soliris (eculizumab) / Alexion Pharma
Clinical, P4 data, Journal: Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. (Pubmed Central) - May 30, 2019
This interim analysis confirmed the acceptable safety profile and effectiveness of eculizumab for Japanese adult aHUS patients in real-world settings. This interim analysis confirmed that eculizumab is well-tolerated and effective for Japanese pediatric patients with aHUS in a real-world setting.
- | Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. (Pubmed Central) - May 29, 2019
...Here we characterize end-stage renal disease (ESRD)-free survival, the rate of thrombotic microangiopathy, organ involvement and the genetic background of 851 patients in the registry, prior to eculizumab treatment...Additionally extrarenal organ manifestations occur in 19%-38% of patients within six months of initial disease presentation (dependent on organ). Thus, our real-world results provide novel insights regarding phenotypic variables and genotypes on the clinical manifestation and progression of aHUS.
- | Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: C3 glomerulopathy in children - is there still a place for anti-cellular immunosuppression? (Pubmed Central) - May 29, 2019
Thus, our real-world results provide novel insights regarding phenotypic variables and genotypes on the clinical manifestation and progression of aHUS. A diverse histological pattern and clinical picture and no known optimal therapy are a hallmark of C3GP.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft. (Pubmed Central) - May 29, 2019
Subsequent hematopoietic stem cell transplantation may ameliorate long-term renal allograft survival. Eculizumab might serve as a bridging therapy until stem cell transplantation.
- ||| Remodulin (treprostinil diethanolamine oral) / United Therapeutics, Soliris (eculizumab) / Alexion Pharma, Actimmune (interferon gamma-1 b) / Horizon
As rare diseases go its certainly not at the top of the list when figure cost over a lifetime Soliris, Ravicti, Actimmune, Crinyze, Remodulin, ERT's, VRTX CF ... (Twitter) - May 24, 2019
- | Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review. (Pubmed Central) - May 24, 2019
Eculizumab might serve as a bridging therapy until stem cell transplantation. No abstract available
- | Campath (alemtuzumab) / Sanofi, Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Roche, Biogen
Journal: Current and emerging treatment options for autoimmune hemolytic anemia. (Pubmed Central) - May 22, 2019
The latter may give hints for targeted therapies (either B or T cell directed) and for new immunomodulatory drugs. Future studies on the genomic landscape in AIHA will further help in designing the best choice, sequence and/or combination of targeted therapies.
- | Soliris (eculizumab) / Alexion Pharma
Review, Journal: How we treat paroxysmal nocturnal hemoglobinuria: a consensus statement of the Canadian PNH Network and review of the national registry. (Pubmed Central) - May 22, 2019
...Introduction of the terminal complement inhibitor eculizumab drastically improved outcomes in PNH patients; however, despite this improvement, there remain several challenges faced by PNH patients and physicians who care for them...Herein we address some of the common diagnostic and therapeutic challenges faced by PNH physicians and give our recommendations. Gaps in knowledge are also addressed and, where appropriate, consensus opinion is provided.
- || Soliris (eculizumab) / Alexion Pharma
Great @threadreaderapp overview & visual abstracts from multiple publications and conferences re atypical HUS #diagnosis, #transplant, types of thrombotic microangiopathy that mimic #aHUS, #eculizumab discontinuation, more. Many thanks @edgarvlermamd https://t.co/gvxJUn57zT (Twitter) - May 17, 2019
- ||| Soliris (eculizumab) / AstraZeneca
Trial completion date, Trial primary completion date: PEGASUS: Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) (clinicaltrials.gov) - May 16, 2019
P3, N=70, Recruiting, Sponsor: Apellis Pharmaceuticals, Inc.
Gaps in knowledge are also addressed and, where appropriate, consensus opinion is provided. Trial completion date: Dec 2019 --> Oct 2020 | Trial primary completion date: Jul 2019 --> Dec 2019
- ||| Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
Trial completion date: ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Na (clinicaltrials.gov) - May 16, 2019
P3, N=246, Active, not recruiting, Sponsor: Alexion Pharmaceuticals
Trial completion date: Dec 2019 --> Oct 2020 | Trial primary completion date: Jul 2019 --> Dec 2019 Trial completion date: Feb 2020 --> Jan 2023
- || Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab-cwvz IV) / AstraZeneca
Trial completion date: ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab (clinicaltrials.gov) - May 16, 2019
P3, N=195, Active, not recruiting, Sponsor: Alexion Pharmaceuticals
Trial completion date: Feb 2020 --> Jan 2023 Trial completion date: Mar 2020 --> Mar 2021
- | Soliris (eculizumab) / Alexion Pharma
Journal: Steroid Responsive Atypical Hemolytic Uremic Syndrome Triggered by Influenza B Infection. (Pubmed Central) - May 15, 2019
Current accepted therapies for aHUS include plasma exchange and eculizumab. We describe a unique patient with aHUS with a rare membrane cofactor protein mutation triggered by influenza B infection, who achieved complete remission with treatment with high-dose corticosteroids after failure of plasmapheresis.
- | Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: An Atypical Case of Atypical Hemolytic Uremic Syndrome. (Pubmed Central) - May 15, 2019
Atypical hemolytic uremic syndrome was suspected and eculizumab was administered resulting in rapid improvement. Genetic analysis revealed a mutation in the gene encoding complement factor H and atypical hemolytic uremic syndrome was confirmed.
- | Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Roche, Biogen
Journal: Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. (Pubmed Central) - May 15, 2019
As there was no response, one dose of eculizumab (900 mg) was then administered with ciprofloxacin as prophylaxis. The patient remains well 6 months post treatment.
- |||||| Soliris (eculizumab) / AstraZeneca
New trial: CHAPLEOMIC: Transcriptome and Metabolic Analyses of CHAPLE Disease (clinicaltrials.gov) - May 15, 2019
P, N=60, Recruiting, Sponsor: Marmara University
- | Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: A Heterozygous CFHR3-CFHR1 Gene Deletion in a Pediatric Patient With Transplant-associated Thrombotic Microangiopathy Who was Treated With Eculizumab. (Pubmed Central) - May 15, 2019
Investigation for the complement alternative pathway showed a heterozygous CFHR3-CFHR1 gene deletion, which is involved in complement activation. The patient might develop TA-TMA as a result of complement regulatory gene mutation.
- | Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire. (Pubmed Central) - May 14, 2019
This study has shown promising validity of the generic module of the PESaM questionnaire. Further research is recommended to assess reliability in greater detail as well as the responsiveness of the measure.
- ||| Soliris (eculizumab) / AstraZeneca
Trial termination: Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis (clinicaltrials.gov) - May 14, 2019
P2, N=14, Terminated, Sponsor: Alexion Pharmaceuticals
Further research is recommended to assess reliability in greater detail as well as the responsiveness of the measure. Completed --> Terminated
- |||| Soliris (eculizumab) / Alexion Pharma
Current concepts in management of aHUS 📌 Treatment guidelines for pregnancy remain limited but Eculizumab appears to be safe in this context 📌 Infectious prophylaxis should focus on encapsulated organisms incl. N. meningitides and S. pneumoniae #NKFClinicals 🇺🇸 #Nephpearls (Twitter) - May 11, 2019
- |||| Soliris (eculizumab) / Alexion Pharma
Retrospective data: SIEDLECKI: Current concepts in mgmt. of aHUS 📌 Plasma exchange is reported in retrospective manner so difficult to compare w/ prospective trials 📌 Eculizumab treatment discontinuation is being considered more frequently in select low risk patients #NKFClinicals 🇺🇸 #Nephpearls (Twitter) - May 11, 2019
- | Soliris (eculizumab) / Alexion Pharma
Journal: Paroxysmal nocturnal hemoglobinuria. (Pubmed Central) - May 11, 2019
Patients with severe hemo-lysis and/or thrombotic complications are indicated for administration of eculizumab - a monoclonal antibody against C5 part of complement. Key words: diagnosis - eculizumab - immunosuppression - paroxysmal nocturnal hemoglobinuria - pathogenesis - transplantation - treatment.
- || inebilizumab (MEDI-551) / Viela Bio, Soliris (eculizumab) / Alexion Pharma, satralizumab (RG6168) / Roche
Eculizumab, Inebilizumab, and Satralizumab will soon emerge as very effective #NMOSD drugs. Stacy Clardey at #AANAM #AANAM2019 (Twitter) - May 10, 2019
- | Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function. (Pubmed Central) - May 9, 2019
4CMenB administration is similarly immunogenic in healthy children and those with asplenia or splenic dysfunction. The significance of the trend to lower responses of SBA titers in complement-deficient children (especially those with terminal chain complement deficiency or those on eculizumab therapy) must be determined by ongoing surveillance for vaccine failures.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Eculizumab is Efficacious But Often Not Accessible. (Pubmed Central) - May 8, 2019
The significance of the trend to lower responses of SBA titers in complement-deficient children (especially those with terminal chain complement deficiency or those on eculizumab therapy) must be determined by ongoing surveillance for vaccine failures. No abstract available
- ||| Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Roche, Biogen
Have one of these now- with smoldering myeloma diagnosed at the same time! Have you see any such co-diagnoses? Had been thinking rituximab... but maybe eculizumab better option.... (Twitter) - May 8, 2019